Streamlining Pulmonology Denial Management for Respiratory Care

Effective **pulmonology denial management** is critical for respiratory care practices navigating complex prior authorization requirements for high-cost therapies and diagnostics.

Denied claims and prior authorizations for pulmonology services, from severe asthma biologics to home oxygen, represent a significant administrative burden and revenue leakage. Manual denial workflows lead to missed timely-filing deadlines, documentation gaps, and ultimately, write-offs. Klivira's automation platform transforms this process, ensuring clinical necessity is effectively communicated and appeals are efficiently processed.

The Challenge of Pulmonology Denials

Pulmonology practices frequently encounter prior authorization denials for high-cost therapies such as asthma biologics (e.g., Dupixent, Nucala, Fasenra, Tezspire), home oxygen, BiPAP, and pulmonary function testing. These denials often stem from intricate payer policies regarding step therapy, specific clinical criteria like eosinophil counts, or the necessity of conservative therapy trials, leading to significant administrative rework for staff.

Common Denial Triggers in Respiratory Care

Specific denial reasons frequently impact pulmonology services. These include step therapy requirements for asthma biologics where payers mandate trials of high-dose inhaled corticosteroids (ICS-LABA), failure to meet specific eosinophil-count thresholds for IL-5-targeting biologics, and insufficient documentation of conservative therapy for idiopathic pulmonary fibrosis (IPF) antifibrotics like pirfenidone (Esbriet) or nintedanib (Ofev). These clinical criteria, often aligned with guidelines like GINA, GOLD, and ATS, necessitate precise documentation and appeal strategies.

Manual Denial Management: Hidden Costs and Inefficiencies

CARC/RARC parsing errors for complex biologic denials, leading to miscategorized reasons.
Missed timely-filing deadlines for high-value appeals due to manual tracking.
Documentation gaps in appeal packets, failing to meet payer-specific requirements or clinical guideline benchmarks.
Lost-to-follow-up appeals for services like home oxygen or BiPAP, resulting in unrecovered revenue.
Write-offs of appealable claims due to staff capacity constraints, rather than clinical merit.

Klivira's Automated Approach to Pulmonology Denial Management

Klivira's platform automates the entire denial management lifecycle for pulmonology, starting with multi-channel denial ingestion from X12 835 and 277 transactions, payer portals, and Da Vinci PAS `ClaimResponse` messages. Our system normalizes X12 CARC/RARC codes and payer-specific variations into a uniform reason set, enabling intelligent auto-routing to the correct claim-correction, appeal, or peer-to-peer pathways.

Key Features for Pulmonology Denial Resolution

Automated ingestion of X12 835 and 277, plus payer portal status for all pulmonology claims and prior authorizations.
Normalization of CARC/RARC codes into a uniform denial reason taxonomy, reducing parsing errors.
Intelligent routing of denials for asthma biologics, home oxygen, and IPF antifibrotics to the appropriate appeal or peer-to-peer pathways based on payer policy.
Automated assembly of appeal packets, pulling relevant clinical documentation from the EMR via FHIR, including eosinophil counts, prior therapies, and exacerbation history.
Timely-filing tracking and automated submission of appeals via payer portals or X12, with proactive deadline enforcement.
Feedback loops identifying denial patterns by payer, service line, or biologic to inform and improve upstream prior authorization submissions.

Integrating Clinical Guidelines for Stronger Appeals

Klivira integrates relevant clinical guidelines, such as those from the American Thoracic Society (ATS), Global Initiative for Chronic Obstructive Lung Disease (GOLD), and Global Initiative for Asthma (GINA), into its denial management logic. This ensures that appeal packets are automatically assembled with the precise documentation required to demonstrate medical necessity, addressing specific criteria like eosinophil counts for biologics or prior controller therapy for severe asthma, thereby strengthening the likelihood of appeal overturns.

The Impact on Revenue Cycle and Patient Care

By automating pulmonology denial management, Klivira helps practices reduce administrative rework, minimize lost revenue from unappealed or mishandled denials, and improve cash flow. The efficiency gained allows staff to focus on higher-value tasks and patient care, while timely and accurate appeals help ensure patients receive necessary respiratory treatments without undue delay. This operational improvement translates directly into enhanced financial performance and patient satisfaction.

Frequently asked questions

How does Klivira handle step-therapy denials for asthma biologics?

Klivira's system is designed to identify step-therapy denials based on normalized CARC/RARC codes and payer policies. It then automates the assembly of appeal packets, ensuring documentation of prior controller therapy at maximum dose or other payer-specific requirements, guided by GINA/GOLD/ATS guidelines, is included for submission.

Can Klivira integrate with our EMR to pull pulmonology-specific clinical notes for appeals?

Yes, Klivira integrates with EMRs via FHIR to automatically pull relevant clinical documentation for appeals. This includes specific pulmonology data such as eosinophil counts, lung function test results, exacerbation history, and notes detailing prior therapies, ensuring comprehensive appeal packets are assembled without manual chart review.

What denial reasons does Klivira typically identify for home oxygen or BiPAP services?

For home oxygen and BiPAP, common denial reasons identified by Klivira include lack of documented medical necessity, insufficient trial of conservative therapy, or failure to meet specific saturation or AHI thresholds. Our system categorizes these reasons and routes the denial to the appropriate appeal pathway, ensuring all required supporting documentation is included.

How does Klivira ensure timely filing for pulmonology appeals?

Klivira enforces per-payer timely-filing windows for all appeals. The system proactively tracks deadlines, provides alerts for upcoming due dates, and automates appeal submission through the appropriate channels, significantly reducing the risk of missed appeal windows and unrecoverable revenue.

Does Klivira provide insights into denial patterns specific to pulmonology services or payers?

Yes, Klivira's reporting and pattern detection capabilities surface denial trends by payer, specific pulmonology service (e.g., asthma biologics, home oxygen), and provider. This data provides actionable insights to inform upstream prior authorization submission improvements, helping to reduce future denials proactively.